Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: One hundred seventy-one patients (85%) were good responders to VBVP, 27 (15%) were poor responders, and four did not respond. With a median follow-up of 74 months (range, 25 to 117 months), the 5-year overall survival rate (mean +/- SD) is 97.5% +/- 2.1%, and the event-free survival rate (mean +/- SD) is 91.1% +/- 1.8%. Significant predictors of worse event-free survival in multivariate analysis were hemoglobin < 10.5 g/L, "b" biologic class, and nodular sclerosis. CONCLUSION:
|
Authors | J Landman-Parker, H Pacquement, T Leblanc, J L Habrand, M J Terrier-Lacombe, Y Bertrand, Y Perel, A Robert, C Coze, I Thuret, J Donadieu, G Schaison, G Leverger, J Lemerle, O Oberlin |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 18
Issue 7
Pg. 1500-7
(Apr 2000)
ISSN: 0732-183X [Print] United States |
PMID | 10735898
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Bleomycin
- Vinblastine
- Etoposide
- Dacarbazine
- Doxorubicin
- Prednisone
|
Topics |
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bleomycin
(administration & dosage)
- Child
- Child, Preschool
- Combined Modality Therapy
- Dacarbazine
(administration & dosage)
- Disease-Free Survival
- Doxorubicin
(administration & dosage)
- Etoposide
(administration & dosage)
- Female
- Hodgkin Disease
(drug therapy, pathology, radiotherapy)
- Humans
- Male
- Prednisone
(administration & dosage)
- Radiotherapy Dosage
- Treatment Outcome
- Vinblastine
(administration & dosage)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|